Stockreport

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

Allurion Technologies, Inc.  (ALUR) 
PDF Average Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 MonthsAll patients remained adherent to tirzepatide for the duration of the study NATICK [Read more]